ClinicalTrials.gg

Program

nomlabofusp

Also written as “CTI-1601” and “Nomlabofusp”.

Its studies are mostly in Friedreich Ataxia, led by Larimar Therapeutics.

Furthest: phase 3, since Aug 17, 20266 company-led studies, 2 open or runningNext primary completion: Jan 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Larimar Therapeutics62 open or runningphase 3since Aug 17, 2026Nov 14, 2019Jan 2027phase 2 · NCT06447025

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 14, 2019First study: phase 1 study in Friedreich AtaxiaFirst studyNCT04176991 · 28 enrolled · United States
  2. Aug 17, 2020Phase 1 study in Friedreich AtaxiaNCT04519567 · 27 enrolled · United States
  3. Oct 5, 2022Phase 2 study in Friedreich AtaxiaNCT05579691 · 28 enrolled · United States
  4. Feb 15, 2024Phase 2 study in Friedreich AtaxiaNCT06447025 · 85 planned · United States
  5. Nov 6, 2024Phase 1 study in Friedreich AtaxiaNCT06681766 · 18 enrolled · United States
  6. Aug 17, 2026Phase 3 study in Friedreich AtaxiaPhase 3 reachedNCT07778836 · 150 planned · United States

Ahead

  1. Jan 2027Primary completion: phase 2 study in Friedreich AtaxiaNCT06447025
  2. Jul 2029Primary completion: phase 3 study in Friedreich AtaxiaNCT07778836

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07778836Friedreich Ataxia · United States3RecruitingJul 2029150
NCT06681766Friedreich Ataxia · United States1TerminatedApr 27, 202518
NCT06447025Friedreich Ataxia · United States2RecruitingJan 202785
NCT05579691Friedreich Ataxia · United States2CompletedDec 4, 202328
NCT04519567Friedreich Ataxia · United States1CompletedMar 16, 202127
NCT04176991Friedreich Ataxia · United States1CompletedOct 31, 202028

How it is read

Names in the registry

  • “CTI-1601”, 4 entries
  • “Nomlabofusp”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.